New hope for tough blood cancers: experimental drug MGD024 enters human testing

NCT ID NCT05362773

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive the drug for up to a year, and doctors will check how the body responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SYSTEMIC MASTOCYTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Colorado Blood Cancer Network

    Denver, Colorado, 80218, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • START - Midwest

    Grand Rapids, Michigan, 49503, United States

  • South Austin Medical Center

    Austin, Texas, 78704, United States

  • University of Maryland, Greenbaum Comprehensive Cancer Center

    Baltimore, Maryland, 21201, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.